NASDAQ:INGN - Inogen Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Inogen Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $46.75 -0.88 (-1.85 %) (As of 01/26/2020 04:00 PM ET) Add Compare Today's Range$45.88Now: $46.75▼$47.8650-Day Range$46.75MA: $64.16▼$72.2752-Week Range$41.19Now: $46.75▼$155.75Volume309,043 shsAverage Volume365,936 shsMarket Capitalization$1.03 billionP/E Ratio32.47Dividend YieldN/ABeta1.63 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Inogen, Inc, a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical appliances & supplies Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:INGN Previous Symbol CUSIPN/A CIK1294133 Webhttp://www.inogen.com/ Phone805-562-0500Debt Debt-to-Equity Ratio0.01 Current Ratio5.79 Quick Ratio5.11Price-To-Earnings Trailing P/E Ratio32.47 Forward P/E Ratio43.29 P/E Growth3.62 Sales & Book Value Annual Sales$358.11 million Price / Sales2.87 Cash Flow$2.90 per share Price / Cash Flow16.11 Book Value$14.54 per share Price / Book3.22Profitability EPS (Most Recent Fiscal Year)$2.30 Net Income$51.85 million Net Margins8.76% Return on Equity9.89% Return on Assets8.03%Miscellaneous Employees1,099 Outstanding Shares22,000,000Market Cap$1.03 billion Next Earnings Date2/25/2020 (Estimated) OptionableOptionable Receive INGN News and Ratings via Email Sign-up to receive the latest news and ratings for INGN and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:INGN Rates by TradingView Inogen (NASDAQ:INGN) Frequently Asked Questions What is Inogen's stock symbol? Inogen trades on the NASDAQ under the ticker symbol "INGN." How were Inogen's earnings last quarter? Inogen Inc (NASDAQ:INGN) released its quarterly earnings results on Tuesday, November, 5th. The medical technology company reported $0.31 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $0.23 by $0.08. The medical technology company earned $91.76 million during the quarter, compared to analysts' expectations of $91.65 million. Inogen had a return on equity of 9.89% and a net margin of 8.76%. The company's quarterly revenue was down 3.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.73 earnings per share. View Inogen's Earnings History. When is Inogen's next earnings date? Inogen is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Inogen. What guidance has Inogen issued on next quarter's earnings? Inogen issued an update on its FY 2019 IntraDay earnings guidance on Monday, January, 13th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $361.4-362.4 million, compared to the consensus revenue estimate of $372.96 million. What price target have analysts set for INGN? 7 equities research analysts have issued twelve-month target prices for Inogen's stock. Their forecasts range from $47.00 to $90.00. On average, they anticipate Inogen's share price to reach $65.00 in the next twelve months. This suggests a possible upside of 39.0% from the stock's current price. View Analyst Price Targets for Inogen. What is the consensus analysts' recommendation for Inogen? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Inogen in the last year. There are currently 1 sell rating, 4 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Inogen. What are Wall Street analysts saying about Inogen stock? Here are some recent quotes from research analysts about Inogen stock: 1. Needham & Company LLC analysts commented, "INGN beat consensus revenue and EPS in 4Q18 and management maintained its 2019 guidance for revenue and adjusted EBITDA. The revenue upside was driven by the DTC sales force expansion and was partially offset by slower domestic B2B sales as a single large customer slowed its orders. Gross margin was up Y/Y and beat our estimate while operating margin was down Y/Y and beat our estimate. INGN continues to see the benefit of its DTC sales force expansion as DTC sales grew 50% in 4Q18. We expect the ongoing sales force expansion, new product cycle, and the market shift to POCs to sustain strong growth and drive upside to consensus and we reiterate our Strong Buy rating." (2/27/2019) 2. According to Zacks Investment Research, "Inogen outperformed the industry in a year’s time. The company continues to gain from its strong portfolio of portable oxygen concentrators (POC) which has been lending it a competitive edge in the MedTech space. Solid business-to-business revenues also buoy optimism. These apart, the company’s direct-to-consumer unit performed exceedingly well in recent times. Moreover, management remains optimistic about its international revenues, which saw solid growth in Europe in recent times. The raised revenue guidance for 2018 is also an added positive. Inogen issued a bullish guidance for 2019 as well. On the flip side, Inogen’s rental revenues declined on a year-over-year basis in recent times. In fact, the company expects rental revenues to remain down in 2018 and grow modestly in 2019. Rising operating expenses are discouraging as well. In the LTOT market, POC adoption continues to face significant headwinds." (2/14/2019) Has Inogen been receiving favorable news coverage? News articles about INGN stock have been trending extremely negative on Sunday, InfoTrie Sentiment reports. InfoTrie rates the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Inogen earned a daily sentiment score of -4.5 on InfoTrie's scale. They also assigned headlines about the medical technology company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the next few days. View News Stories for Inogen. Are investors shorting Inogen? Inogen saw a drop in short interest in December. As of December 13th, there was short interest totalling 2,340,000 shares, a drop of 6.8% from the November 28th total of 2,510,000 shares. Based on an average daily volume of 342,300 shares, the days-to-cover ratio is currently 6.8 days. Currently, 12.9% of the shares of the stock are sold short. View Inogen's Current Options Chain. Who are some of Inogen's key competitors? Some companies that are related to Inogen include Wright Medical Group (WMGI), Avanos Medical (AVNS), Establishment Labs (ESTA), Sientra (SIEN), RTI Surgical (RTIX), Invacare (IVC), Lakeland Industries (LAKE), ConforMIS (CFMS), Histogenics (HSGX), COLLPLANT HOLDI/S (CLGN), Rewalk Robotics (RWLK), NanoVibronix (NAOV), Ocugen (OCGN), Precision Therapeutics (POAI) and Bionik Laboratories (BNKL). What other stocks do shareholders of Inogen own? Based on aggregate information from My MarketBeat watchlists, some companies that other Inogen investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Medivation (MDVN), NVIDIA (NVDA), Alibaba Group (BABA), First Solar (FSLR), Netflix (NFLX), Micron Technology (MU) and Paypal (PYPL). Who are Inogen's key executives? Inogen's management team includes the folowing people: Mr. Scott Wilkinson, CEO, Pres & Director (Age 54)Mr. Brenton Taylor, Co-founder & Exec. VP of Engineering (Age 38)Ms. Alison Perry Bauerlein, Co-founder, Exec. VP of Fin., CFO, Corp. Sec. & Treasurer (Age 38)Mr. Bart Sanford, Exec. VP of Operations (Age 53)Mr. Byron Myers, Exec. VP of Sales & Marketing (Age 40) Who are Inogen's major shareholders? Inogen's stock is owned by many different of institutional and retail investors. Top institutional investors include Riverbridge Partners LLC (1.23%), Summit Creek Advisors LLC (0.66%), New York State Teachers Retirement System (0.15%), Chicago Capital LLC (0.12%), State of Alaska Department of Revenue (0.06%) and Curbstone Financial Management Corp (0.05%). Company insiders that own Inogen stock include Alison Bauerlein, Brenton Taylor, Byron Myers, Heath Lukatch, Heather D Rider, Loren L Mcfarland, Matt Scribner, Ray Benjamin M Anderson, Raymond Huggenberger and Scott Wilkinson. View Institutional Ownership Trends for Inogen. Which major investors are selling Inogen stock? INGN stock was sold by a variety of institutional investors in the last quarter, including Riverbridge Partners LLC, CWM Advisors LLC, Summit Creek Advisors LLC, Chicago Capital LLC, Curbstone Financial Management Corp, Louisiana State Employees Retirement System and State of Alaska Department of Revenue. View Insider Buying and Selling for Inogen. Which major investors are buying Inogen stock? INGN stock was purchased by a variety of institutional investors in the last quarter, including New York State Teachers Retirement System. Company insiders that have bought Inogen stock in the last two years include Heath Lukatch and Loren L Mcfarland. View Insider Buying and Selling for Inogen. How do I buy shares of Inogen? Shares of INGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Inogen's stock price today? One share of INGN stock can currently be purchased for approximately $46.75. How big of a company is Inogen? Inogen has a market capitalization of $1.03 billion and generates $358.11 million in revenue each year. The medical technology company earns $51.85 million in net income (profit) each year or $2.30 on an earnings per share basis. Inogen employs 1,099 workers across the globe.View Additional Information About Inogen. What is Inogen's official website? The official website for Inogen is http://www.inogen.com/. How can I contact Inogen? Inogen's mailing address is 326 BOLLAY DRIVE, GOLETA CA, 93117. The medical technology company can be reached via phone at 805-562-0500 or via email at [email protected] MarketBeat Community Rating for Inogen (NASDAQ INGN)Community Ranking: 3.0 out of 5 ( )Outperform Votes: 356 (Vote Outperform)Underperform Votes: 229 (Vote Underperform)Total Votes: 585MarketBeat's community ratings are surveys of what our community members think about Inogen and other stocks. Vote "Outperform" if you believe INGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INGN will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/26/2020 by MarketBeat.com StaffFeatured Article: What is a balanced fund?
